Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Kite Pharma: Interpretation of Results from the Interim Look at ZUMA-1 (KITE, Avoid, $60.25)

Overview

Kite released a press release with topline data on the interim look at the ZUMA-1 trial. This note interprets information…
Read more…